Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | SAFE: cardioprotective strategy for non-metastatic BC patients receiving anthracycline-based chemo

Icro Meattini, MD, University of Florence, Florence, Italy, explores cardioprotective strategies for patients with non-metastatic breast cancer (BC) who are receiving an anthracycline-based chemotherapy, as evaluated in the SAFE trial (NCT2236806). In this Phase III study, results suggested that cardioprotective pharmacological strategies in patients who were affected by breast cancer and were receiving anthracycline-based chemotherapy are well tolerated and seem to protect against cancer therapy-related left ventricular ejection fraction decline and heart remodeling. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.